SOURCE-LINKED STUDY SUMMARY
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Abstract summarizedQuality not appraised
- What was studied
- Phase 3 randomized trial comparing semaglutide with placebo for metabolic fatty liver inflammation and scarring.
- Who / model studied
- The reported analysis included 800 patients with biopsy-confirmed liver inflammation and fibrosis stage 2 or 3, assessed at 72 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Both primary outcomes favored semaglutide: inflammation resolved without worse scarring in 62.9% versus 34.3%; scarring improved without worse inflammation in 36.8% versus 22.4%. Secondary results showed both improvements together in 32.7% versus 16.1%, and weight loss of 10.5% versus 2.0%. Pain scores did not clearly differ. Digestive adverse events were more common.
- Limitations & context
- This was a planned interim analysis of the first 800 participants in an ongoing 1197-patient trial planned for 240 weeks.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2413258